Top Stock Reports For Boeing, Lockheed Martin & Anthem
Zacks Investment Research | Apr 05, 2019 03:37AM ET
Friday, April 5, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Lockheed Martin (LMT) and Anthem (NYSE:ANTM). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
Strong Buy-ranked Boeing’s shares have gained +17.6% in the past year, outperforming the Zacks Aerospace & Defense industry, which declined -3.5% during the same time period. The Zacks analyst emphasizes that the company is the largest aircraft manufacturer in the world.
The company’s 20-year market outlook forecasts commercial jetliner demand to increase by 4.1%. Single-aisle jets are expected to be the major driver behind this growth. Boeing expects commercial orders to be fueled by sustained annual growth in commercial passenger traffic along with a big wave of retiring, old planes. Its strong balance sheet and cash flows provide financial flexibility in matters of incremental dividend, ongoing share repurchases and earnings accretive acquisitions.
Its revenue exposure is also spread across more than 90 countries around the globe. However, the aerospace giant may face competitive challenges once new manufacturers like China enters the commercial jet space.
(You can ).
Shares of Lockheed Martin have lost -13.6% in the past year, underperforming the Zacks Aerospace Defense industry, which has declined -3.5% over the same period. The Zacks analyst thinks that since it is the largest defense contractor in the world, Lockheed Martin enjoys a strong demand for its high-end military equipment in domestic as well as international markets.
Consequently, robust order growth has been a primary growth driver for this company. The F-35 program continues to be a primary growth driver for the company. Lockheed Martin frequently procures significant contracts that are a major growth driver for its revenues.
However it faces intense competition for its broad portfolio of products and services in both domestic and international markets. It remains subject to interest rate risk related to the issuance of debt.
(You can ).
Buy-ranked Anthem’s shares have outperformed the Zacks Medical Insurance industry's rally in the past year (up +26.2% vs. +8.2%). Moreover, it has witnessed its 2019 and 2020 earnings estimates move north over the last 30 days. The Zacks analyst thinks the company's prudent acquisitions complement its organic growth.
Get The News You Want
Its consistently growing topline paves the way for long-term growth. A diverse product portfolio has also helped the company enhance its underwriting results. Anthem’s strong capital position backs effective capital deployment via share buybacks and regular dividends. A strong outlook for 2019 instills investor's confidence in the company.
However, its declining membership is a persistent concern. Also, the company has been suffering from high benefit costs and rising selling, general and administrative expenses.
(You can ).
Other noteworthy reports we are featuring today include AbbVie (ABBV), Colgate-Palmolive (CL) and Delta Air Lines (NYSE:DAL).
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly
Today's Must Read/h6
Featured Reports/h6
The Zacks analyst likes Cheniere's competitive advantage of being the first and dominant natural gas exporter in the U.S. market but is concerned about the huge debt load of $28 billion.
Per the Zacks analyst, extended partnerships with the likes of Comcast (NASDAQ:CMCSA) and Viacom related to new content production are expected to boost Snap's audience base as well as user engagement.
While Mosaic's debt load is a concern, the company should gain from synergies of the Vale Fertilizantes acquisition in 2019, according to the Zacks analyst.
Per the Zacks analyst, strong traction of Graco's Industrial segment, fueled by broad-based market demand for its products should continue to drive revenues. High tariff costs remain a concern.
Robust construction activity, mainly in the non-residential markets, along with aggressive acquisitions will help EMCOR to drive profits, per the Zacks analyst.
Per the Zacks analyst, higher loans and deposits, and inorganic growth efforts will support Bank OZK's revenues.
Per the Zacks analyst, Canadian Solar has a strong pipeline of projects and carries out various acquisitions to further consolidate its position.
The Zacks analyst likes Cheniere's competitive advantage of being the first and dominant natural gas exporter in the U.S. market but is concerned about the huge debt load of $28 billion.
Per the Zacks analyst, extended partnerships with the likes of Comcast (NASDAQ:CMCSA) and Viacom related to new content production are expected to boost Snap's audience base as well as user engagement.
While Mosaic's debt load is a concern, the company should gain from synergies of the Vale Fertilizantes acquisition in 2019, according to the Zacks analyst.
Per the Zacks analyst, strong traction of Graco's Industrial segment, fueled by broad-based market demand for its products should continue to drive revenues. High tariff costs remain a concern.
Robust construction activity, mainly in the non-residential markets, along with aggressive acquisitions will help EMCOR to drive profits, per the Zacks analyst.
Per the Zacks analyst, higher loans and deposits, and inorganic growth efforts will support Bank OZK's revenues.
Per the Zacks analyst, Canadian Solar has a strong pipeline of projects and carries out various acquisitions to further consolidate its position.
New Upgrades/h6
Per the Zacks analyst, innovation and in-store implementation have been guiding principles for Colgate's growth strategy, enabling it to capture market share in all regions and categories.
The Zacks analyst appreciates the performance of Delta with respect to unit revenues mainly due to the strong demand for air travel. Initiatives to reward shareholders also bode well.
Per the Zacks analyst, Corcept's Cushing's syndrome drug Korlym shows high growth potential. The company's efforts to expand the drug's label also hold promise and bodes well for long-term growth.
Per the Zacks analyst, innovation and in-store implementation have been guiding principles for Colgate's growth strategy, enabling it to capture market share in all regions and categories.
The Zacks analyst appreciates the performance of Delta with respect to unit revenues mainly due to the strong demand for air travel. Initiatives to reward shareholders also bode well.
Per the Zacks analyst, Corcept's Cushing's syndrome drug Korlym shows high growth potential. The company's efforts to expand the drug's label also hold promise and bodes well for long-term growth.
New Downgrades/h6
The Zacks analyst believes that while U.S. Humira and hematological oncology franchise growth will drive sales in 2019, the loss of international Humira revenues to biosimilars will be a big headwind.
Per the Zacks analyst, revenues at this segment have remained weak for the past many years, due to weakness in its U.K business. Despite turnaround initiatives, their is need for caution.
The Zacks analyst is apprehensive about headwinds in AngioDynamics' Venous Insufficiency business and a sluggishness in radiofrequency ablation products.
The Zacks analyst believes that while U.S. Humira and hematological oncology franchise growth will drive sales in 2019, the loss of international Humira revenues to biosimilars will be a big headwind.
Per the Zacks analyst, revenues at this segment have remained weak for the past many years, due to weakness in its U.K business. Despite turnaround initiatives, their is need for caution.
The Zacks analyst is apprehensive about headwinds in AngioDynamics' Venous Insufficiency business and a sluggishness in radiofrequency ablation products.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.